JPWO2023163227A5 - - Google Patents
Info
- Publication number
- JPWO2023163227A5 JPWO2023163227A5 JP2024503324A JP2024503324A JPWO2023163227A5 JP WO2023163227 A5 JPWO2023163227 A5 JP WO2023163227A5 JP 2024503324 A JP2024503324 A JP 2024503324A JP 2024503324 A JP2024503324 A JP 2024503324A JP WO2023163227 A5 JPWO2023163227 A5 JP WO2023163227A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- group
- alkyl
- optionally substituted
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022030070 | 2022-02-28 | ||
| JP2022067814 | 2022-04-15 | ||
| JP2022106430 | 2022-06-30 | ||
| PCT/JP2023/007414 WO2023163227A1 (ja) | 2022-02-28 | 2023-02-28 | 抗体－薬物コンジュゲート |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2023163227A1 JPWO2023163227A1 (https=) | 2023-08-31 |
| JPWO2023163227A5 true JPWO2023163227A5 (https=) | 2026-03-10 |
Family
ID=87766350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024503324A Pending JPWO2023163227A1 (https=) | 2022-02-28 | 2023-02-28 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250235547A1 (https=) |
| EP (1) | EP4487873A1 (https=) |
| JP (1) | JPWO2023163227A1 (https=) |
| KR (1) | KR20240151847A (https=) |
| CN (1) | CN119095625A (https=) |
| AU (1) | AU2023226367A1 (https=) |
| CA (1) | CA3252358A1 (https=) |
| MX (1) | MX2024010507A (https=) |
| WO (1) | WO2023163227A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117024438A (zh) * | 2022-07-29 | 2023-11-10 | 杭州爱科瑞思生物医药有限公司 | 依沙替康衍生物及其应用 |
| CN117417347A (zh) * | 2023-09-28 | 2024-01-19 | 杭州爱科瑞思生物医药有限公司 | 卤素取代的依沙替康的酰胺衍生物及其制备方法和应用 |
| WO2025183174A1 (ja) * | 2024-03-01 | 2025-09-04 | 株式会社ペルセウスプロテオミクス | 抗ｃｄｈ３ヒト化抗体と薬物とのコンジュゲート、およびその使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100506277C (zh) | 2001-11-01 | 2009-07-01 | Uab研究基金会 | 肿瘤坏死因子相关细胞凋亡诱导配体受体的选择性抗体和其它治疗剂的联合体系 |
| CA2467242A1 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
| DK2907824T3 (en) | 2012-10-11 | 2018-07-23 | Daiichi Sankyo Co Ltd | ANTIBODY-drug conjugate |
| EP2910573B1 (en) * | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
| EP3160513B1 (en) | 2014-06-30 | 2020-02-12 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| CN118652192A (zh) * | 2017-05-24 | 2024-09-17 | 德克萨斯州大学系统董事会 | 用于抗体药物缀合物的接头 |
-
2023
- 2023-02-28 CA CA3252358A patent/CA3252358A1/en active Pending
- 2023-02-28 CN CN202380036370.8A patent/CN119095625A/zh active Pending
- 2023-02-28 EP EP23760225.5A patent/EP4487873A1/en active Pending
- 2023-02-28 JP JP2024503324A patent/JPWO2023163227A1/ja active Pending
- 2023-02-28 US US18/840,991 patent/US20250235547A1/en active Pending
- 2023-02-28 WO PCT/JP2023/007414 patent/WO2023163227A1/ja not_active Ceased
- 2023-02-28 KR KR1020247031868A patent/KR20240151847A/ko active Pending
- 2023-02-28 AU AU2023226367A patent/AU2023226367A1/en active Pending
-
2024
- 2024-08-27 MX MX2024010507A patent/MX2024010507A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2023163227A5 (https=) | ||
| EP4331611A1 (en) | Preparation method and application of antibody drug conjugate | |
| JP2023051977A (ja) | アマニタ毒素の誘導体及びそれらと細胞結合分子との共役体 | |
| JP2024112832A (ja) | 分岐連結体を有する細胞結合分子と細胞毒性剤との共役体 | |
| TWI877186B (zh) | 抗體-干擾素基因刺激蛋白(sting)促效劑結合物及其於免疫療法之用途 | |
| JP2023530128A (ja) | 細胞結合分子とカンプトテシン類縁体との共役体 | |
| KR20230008723A (ko) | 전하 변이체 링커 | |
| JP2026026483A (ja) | 標的化デンドリマー複合体 | |
| KR102574659B1 (ko) | 비선형 자가 희생 링커 및 이의 접합체 | |
| TW202313123A (zh) | 蒽環黴素抗體結合物 | |
| CN110099682A (zh) | 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用 | |
| JP2020510656A5 (https=) | ||
| TW202034956A (zh) | 包含抗191p4d12抗體藥物結合物之醫藥組合物及其使用方法 | |
| CN119156231A (zh) | 提高鹅膏蕈毒素-抗体缀合物的治疗指数的方法 | |
| JPWO2023163234A5 (https=) | ||
| JP2022514348A (ja) | チオール多重リンカーを有するａｄｃ | |
| KR20240041969A (ko) | 접합 시약 및 이의 접합체 | |
| WO2025207828A1 (en) | Nanocomposition comprising modified exatecan and use thereof | |
| RU2024128520A (ru) | Конъюгат антитело-лекарственное средство | |
| EP4570272A1 (en) | New drug complex | |
| JP2025123209A (ja) | 新薬物複合体 | |
| RU2826228C2 (ru) | Конъюгаты антитело-sting агонист и их применение в иммунотерапии | |
| RU2024139362A (ru) | Конъюгат антитела и нескольких лекарственных средств | |
| WO2026022310A1 (fr) | Conjugue anticorps-medicament comprenant un anticorps anti-pmel-17 et ses utilisations | |
| JP2023517477A (ja) | デュオカルマイシン誘導体含有抗体薬物複合体及びチオ硫酸類を含む組合せ |